FINWIRES · TerminalLIVE
FINWIRES

美国石油市场最新消息:和平谈判破裂,油轮被扣押,油价连续第四天上涨

-- 周四,由于外交努力破裂,油价连续第四个交易日上涨,与此同时,美伊之间的紧张局势升级。 布伦特原油期货合约上涨0.8%,至每桶102.67美元。西德克萨斯中质原油期货合约上涨1.2%,至每桶94.07美元。 盛宝银行分析师表示:“由于伊朗和美国都试图封锁霍尔木兹海峡,而这场严重扰乱全球几种关键大宗商品供应的战争仍看不到尽头,油价连续第四个交易日走高,布伦特原油价格在每桶103美元左右波动。” 他们补充道:“特朗普表示,在华盛顿等待修改后的和平方案期间,停火协议将无限期有效,但伊朗已表示近期没有举行会谈的计划。” 专家表示,伊朗在霍尔木兹海峡扣押两艘油轮,加上五角大楼估计清除该水道的水雷可能需要六个月时间,市场正在积极调整价格,以应对可能持续的供应危机。 周四,美军在印度洋扣押了受制裁的油轮“Majestic X”号,海上对峙局势骤然升级。 此前有报道称,另有三艘悬挂伊朗国旗的船只被拦截,五角大楼估计,清除霍尔木兹海峡的水雷可能需要长达六个月的时间。 事态显著升级,特朗普总统通过社交媒体直接下令美国海军“击毙”任何被发现在该水道布雷的小型船只。 总统表示“不容犹豫”,并补充说,伊朗海军舰队已被严重摧毁,159艘舰艇“沉入海底”。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA